Sanofi announces new VP of External Affairs
pharmafile | January 30, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Sanofi
Kathleen Tregoning has been announced as Sanofi’s vice president of External Affairs and as a new member of the Executive Committee. In the role, she will take up leadership of the firm’s External Affairs organisation which covers Market Access, Public Affairs, Government Affairs, Corporate Communications, Global Policy, and Corporate Social Responsibility.
Tregoning comes to the company from Biogen where she held the position of senior vice president of Corporate Affairs. She has held previous healthcare roles in the United States Senate and United States House of Representatives, joining Biogen in 2006 as vice president, Public Policy & Government Affairs. Throughout her career, Tregoning has amassed over 20 years of policy, advocacy, stakeholder outreach and external engagement experience.
Sanofi CEO Olivier Brandicourt said of Tregoning’s appointment: “Kathleen brings a unique set of talents and experience to Sanofi that combines a deep political and policy expertise with highly relevant corporate experience in the biopharmaceutical industry. Working closely with the entire executive leadership team, Kathleen will lead our efforts to drive a better understanding of the value of our innovations among external stakeholders and ensure appropriate market access for our various healthcare offerings.”
Tregoning will step into the role on 27 February.
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
